Multi Cancer Early Detection Market Companies
- Burning Rock Biotech
- Exact Sciences
- Thrive Earlier Detection
- Foundation Medicine
- Genomic Health
- Freenome
- VolitionRX
- CellMax Life
- Guardant Health
- Elypta
- StageZero Life Sciences
- GRAIL
- C2i Genomics
- ArcherDX
- 1drop Inc.
Recent News:
- Freenome, a biotechnology business that develops blood tests for early cancer detection, raised $254 million from new and current shareholders in February 2024. The funding will allow Freenome to develop a pipeline of single-cancer and tailored multi-cancer early detection tests using its multi-omics platform. They are grateful for their investors' support and confidence. They are committed to addressing the critical need for better cancer screening options as we aim to make early cancer detection more convenient, accessible, and actionable for everyone. With this support, they will be able to fully realize our technology's potential for early cancer detection testing.
- The National Institutes of Health (NIH) established a clinical trials network in February 2024 to investigate new cancer detection technologies. The Cancer Screening Research Network (CSRN) supports the Biden-Harris administration's Cancer Moonshot? by prioritizing early cancer detection for better treatment options. The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), has funded eight groups to carry out the network's initial activities.
- According to a new study published in BMJ Oncology, a unique blood test could detect 18 different forms of cancer at an early stage by January 2024. The test was designed with the proteome trusted Source in mind, which refers to the whole collection of proteins in the body. Gender-specific liquid biopsy tests, according to a study led by Dr. Ashkan Afshin, an affiliate associate professor of health metrics sciences at the University of Washington's Institute for Health Metrics and Evaluation, Trusted Source, which analyzes the presence of protein biomarkers for various types of cancer in the bloodstream, can detect stage 1 cancers 93% of the time in men and 84% in women.